: REGENERATE showed that OCA treatment improved histological liver fibrosis in NASH patients.1 Liver biopsy is an impractical tool to monitor patient response to therapy. Non-invasive tests have been shown to be predictive of histologic changes and liver-related outcomes in NASH. Here, we evaluate the potential utility of non-invasive tests in monitoring NASH patients with fibrosis during treatment.